- Home
- GNTA vs EYEN Comparison
GNTA vs EYEN Comparison
Compare GNTA & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- EYEN
- Stock Information
- Founded
- GNTA 2014
- EYEN 2014
- Country
- GNTA Italy
- EYEN United States
- Employees
- GNTA N/A
- EYEN N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- EYEN Health Care
- Exchange
- GNTA Nasdaq
- EYEN Nasdaq
- Market Cap
- GNTA 67.4M
- EYEN 38.2M
- IPO Year
- GNTA 2021
- EYEN 2018
- Fundamental
- Price
- GNTA $5.34
- EYEN $0.55
- Analyst Decision
- GNTA Strong Buy
- EYEN Strong Buy
- Analyst Count
- GNTA 1
- EYEN 2
- Target Price
- GNTA $25.00
- EYEN $12.00
- AVG Volume (30 Days)
- GNTA 28.4K
- EYEN 879.0K
- Earning Date
- GNTA 01-01-0001
- EYEN 11-11-2024
- Dividend Yield
- GNTA N/A
- EYEN N/A
- EPS Growth
- GNTA N/A
- EYEN N/A
- EPS
- GNTA N/A
- EYEN N/A
- Revenue
- GNTA N/A
- EYEN $31,405.00
- Revenue This Year
- GNTA N/A
- EYEN $50,309.30
- Revenue Next Year
- GNTA N/A
- EYEN $421.63
- P/E Ratio
- GNTA N/A
- EYEN N/A
- Revenue Growth
- GNTA N/A
- EYEN N/A
- 52 Week Low
- GNTA $2.20
- EYEN $0.37
- 52 Week High
- GNTA $7.28
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- EYEN 52.60
- Support Level
- GNTA $4.89
- EYEN $0.52
- Resistance Level
- GNTA $6.20
- EYEN $0.59
- Average True Range (ATR)
- GNTA 0.70
- EYEN 0.05
- MACD
- GNTA -0.06
- EYEN 0.01
- Stochastic Oscillator
- GNTA 37.32
- EYEN 66.45
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.